BioTrends Announces a New Syndicated Report Series: LaunchTrends®: Aubagio

EXTON, Pa. --(Business Wire)--

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, announces a new syndicated report series entitled LaunchTrends: Aubagio. Aubagio (teriflunomide) is a new once-daily, oral disease-modifying agent (DMA) indicated for patients with relapsing forms of multiple sclerosis (MS). BioTrends has been following neurologists' perception of Aubagio in its TreatmentTrends^®: Multiple Sclerosis (US) report series since 2009. According to the most recent TreatmentTrends: Multiple Sclerosis (US) report, 57 percent of neurologists express aided awareness of Aubagio and 48 percent have a high level of interest in learning more about the product. As only the second oral DMA to enter the market, following the launch of Novartis's Gilenya in 2010, surveyed neurologists believe that much of the potential clinical value of Aubagio will be driven more by Aubagio's route of administration and less by perceptions related to efficacy.

LaunchTrends: Aubagio is a four-wave syndicated report series that will specifically track the introduction of Aubagio into the market, based on data collected at one month, three months, six months and one year post-commercial availability of Aubagio. Each wave will inclde a quantitative survey with 75+ neurologists and qualitative interviews with a subset of 15 survey respondents. Along with awareness and sources of familiarity, the reports are designed to assess neurologists' trial, adoption and usage, including anticipated future trends, of Aubagio within the MS market. The reports will also provide information on product perceptions, satisfaction, obstacles to use, reasons for use, patient types, displacement of competitors, Sanofi promotional efforts, and benchmarking against other newly approved agents. With the October 1^st commercial availability of Aubagio, the first wave of the survey was fielded November 12-13 and the final report will be available on December 21.

In addition to the LaunchTrends: Aubagio report series, BioTrends will track the U.S. uptake of Aubagio in the quarterly TreatmentTrends: Multiple Sclerosis (US) report series and the annual ChartTrends^®: Multiple Sclerosis (US) patient audit of 1,000+ MS patients. These reports provide a broader MS market landscape view, including all currently approved DMAs and DMAs in late-stage clinical development.

About BioTrends Research Group

BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 321-9400 or www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.